Background Vaccines have been demonstrated to protect against high-risk human
papillomavirus infection (HPV), including HPV-16/18, and cervical lesions among HIV …

The prophylactic vaccines available to protect against infections by HPV are well tolerated
and highly immunogenic. People with HIV have a higher risk of developing HPV infection …

Background Men and women with HIV infection are at increased risk of developing cancers
associated with human papillomavirus (HPV). The two licensed prophylactic HPV vaccines …

Objective To evaluate the immunogenicity and safety of the quadrivalent HPV (qHPV)
vaccine in HIV-positive women over 24 months. Design Between November 2008 and …

Objectives Despite their use, differences in human papillomavirus (HPV) vaccine efficacies
remain uncertain. This study assesses efficacy differences among bivalent, quadrivalent …

Background The objective of this study was to determine whether the 3-dose quadrivalent
human papillomavirus (HPV) vaccine series (HPV-6,-11,-16,-18) is immunogenic and safe in …

Human immunodeficiency virus (HIV)-infected women carry a significant burden on human
papillomavirus (HPV) infection and associated diseases. As HIV-infected individuals are …

Introduction Human papillomavirus (HPV) infection, which poses significant disease burden,
is decreasing following implementation of vaccination programs. Synthesized evidence on …

Prophylactic human papillomavirus (HPV) vaccine represents a revolutionary step forward in
preventing HPV-related cancers, especially cervical carcinoma. Alongside appropriate …

Background Uptake of human papillomavirus (HPV) vaccine remains low in many countries,
although the bivalent and quadrivalent HPV vaccines given as a three‐dose schedule are …